GPR18 Antibody

What is GPR18 and why is it important in research?

GPR18 is a G-protein coupled receptor (GPCR) that functions as a putative cannabinoid receptor, binding specific ligands such as N-arachidonoyl glycine (NAGly) to facilitate intracellular communication and response to environmental changes . This receptor is of significant research interest due to its involvement in the endocannabinoid signaling system and its important role in immune function regulation . GPR18 is highly expressed in tissues including spleen, thymus, testis, small intestine, and certain regions of the brain, suggesting its diverse physiological roles across multiple systems . The receptor mediates several cellular functions including migration, regulation of intraocular and blood pressure, and potentially plays a role in the homeostasis of intestinal intraepithelial lymphocytes . The involvement of GPR18 in various biological processes makes it a compelling target for research in fields ranging from immunology to neuroscience, with potential implications for therapeutic development targeting inflammatory disorders, immune regulation, and possibly even cancer, as it has been identified as one of the most highly expressed GPCRs in metastatic melanoma .

What types of GPR18 antibodies are available for research applications?

Research laboratories have access to several types of GPR18 antibodies that vary in their host species, target epitopes, and validated applications . Polyclonal antibodies, such as the rabbit polyclonal antibodies described in the search results, are commonly used and can recognize multiple epitopes on the GPR18 protein . Some antibodies target the extracellular domains of GPR18, like the N-terminus (amino acid residues 7-22 in mouse GPR18), making them particularly useful for applications requiring detection of the native protein on the cell surface, such as flow cytometry on intact cells . Others target intracellular domains or synthetic peptide sequences within the human GPR18 protein . Available antibodies have been validated for various applications including Western blot (WB), immunocytochemistry/immunofluorescence (ICC/IF), immunohistochemistry (IHC), and flow cytometry . The specificity of these antibodies varies, with some demonstrating cross-reactivity between species (particularly mouse and rat) due to sequence homology . When selecting an antibody, researchers should consider the specific experimental requirements, including the application method, target species, and whether detection of native or denatured protein is needed, as well as the validation data available for each antibody to ensure reliable and reproducible results.

How is GPR18 expression distributed across different tissues and cell types?

GPR18 exhibits a distinct expression pattern across various tissues and cell types, with highest expression levels observed in immune system components and certain specialized tissues . According to mRNA localization studies in mouse tissue, GPR18 shows strongest expression in the spleen and bone marrow, followed by thymus, lung, and cerebellar tissue . This receptor is also abundantly expressed in testis and small intestines, suggesting specialized functions in these organs . At the cellular level, GPR18 is prominently expressed in cells of the immune system, including lymphocytes, particularly in CD8+ subsets of intraepithelial lymphocytes in the small intestine . The receptor has been detected in microglial cells, which are the resident immune cells of the central nervous system, implicating its role in neuroinflammatory processes . Additionally, GPR18 expression has been reported in endometrial cells and, notably, is one of the most highly expressed G-protein coupled receptors in metastatic melanoma, suggesting a potential role in tumor progression . Immunohistochemical studies have visualized GPR18 expression in specific brain regions, such as the rat cingulate cortex and dorsomedial hypothalamus, indicating its potential involvement in central nervous system functions . The diverse expression pattern of GPR18 across multiple tissues and cell types highlights its potential involvement in a wide range of physiological processes and disease states, making it an important target for multidisciplinary research.

What are the validated applications for detecting GPR18 using antibodies?

GPR18 antibodies have been validated for multiple experimental applications, enabling researchers to investigate this receptor's expression, localization, and function across various biological contexts . Western blot (WB) analysis represents a fundamental application, allowing for detection of GPR18 protein in tissue lysates and cell lines, with validated results in rat and mouse brain lysates as well as immune cell lines such as EL4 T-cell lymphoma, WEHI-231 B-cell lymphoma, and BV-2 microglia cells . Immunohistochemistry (IHC) applications have successfully visualized GPR18 expression patterns in perfusion-fixed frozen brain sections, particularly in regions such as the rat cingulate cortex and dorsomedial hypothalamus, providing valuable insights into the neuroanatomical distribution of this receptor . Immunocytochemistry and immunofluorescence (ICC/IF) techniques enable examination of GPR18 subcellular localization, with antibodies recognizing either epitope tags (such as HA) incorporated into the N-terminus of recombinant GPR18 or natural epitopes within the receptor's structure . Flow cytometry represents another powerful application, particularly with antibodies targeting extracellular domains of GPR18, allowing detection of the receptor on the surface of intact live cells without permeabilization, as demonstrated in BV-2 microglia cells . These diverse applications provide researchers with a comprehensive toolkit for investigating GPR18 expression patterns, protein levels, cellular and subcellular localization, and potentially functional states across different experimental systems, thereby facilitating a deeper understanding of this receptor's biological roles and regulatory mechanisms.

How should GPR18 antibodies be validated for experimental use?

Thorough validation of GPR18 antibodies is essential to ensure experimental reliability and accurate interpretation of results, requiring a multi-faceted approach to confirm specificity and performance characteristics . Primary validation should include the use of blocking peptides, where pre-incubation of the antibody with the immunizing peptide should abolish or significantly reduce signal in all applications, as demonstrated in Western blot analyses of brain and immune cell lysates and immunohistochemical staining of brain sections . Orthogonal validation using complementary techniques is also crucial; for example, correlating protein detection by immunoblotting with mRNA expression data from RNA sequencing can provide additional confidence in antibody specificity . Cross-reactivity testing across various tissues and cell types that differentially express GPR18 should reveal expression patterns consistent with published literature on GPR18 distribution, with expected signals in spleen, thymus, and certain brain regions, and appropriate negative controls showing minimal background . For recombinant systems, parallel detection using antibodies against both the native protein and epitope tags (such as HA) can confirm specific recognition of the target protein . Finally, validation should include genetic approaches where possible, such as testing the antibody in tissues from GPR18 knockout models or in cells following GPR18 knockdown by RNA interference, which should result in absence or significant reduction of signal compared to wild-type samples . These rigorous validation steps collectively ensure that observed signals genuinely represent GPR18 rather than non-specific binding or cross-reactivity with other proteins, thereby establishing the antibody as a reliable tool for investigating this receptor across various experimental contexts.

What are the optimal conditions for Western blotting using GPR18 antibodies?

Successful Western blotting for GPR18 detection requires careful optimization of several critical parameters to ensure specific and robust signal detection while minimizing background issues . Sample preparation represents a crucial initial step, with effective lysis buffers typically containing detergents suitable for membrane protein extraction (such as Triton X-100 or CHAPS), protease inhibitors to prevent degradation, and phosphatase inhibitors if phosphorylation states are of interest . For gel electrophoresis, 10-12% SDS-PAGE gels generally provide appropriate resolution for GPR18, which has a predicted molecular weight of approximately 38 kDa, though the observed size may vary due to post-translational modifications or alternative splicing . After transfer to nitrocellulose or PVDF membranes, blocking with 5% non-fat dry milk or BSA in TBS-T for 1-2 hours at room temperature typically provides effective blocking of non-specific binding sites . Primary antibody incubation with validated GPR18 antibodies should follow manufacturer recommendations, though dilutions in the range of 1:500 to 1:1000 for most commercial antibodies are typically effective when incubated overnight at 4°C . Multiple washing steps with TBS-T (at least 3 × 10 minutes) are essential both after primary and secondary antibody incubations to reduce background . For detection, HRP-conjugated secondary antibodies matching the host species of the primary antibody (typically anti-rabbit for many commercial GPR18 antibodies) should be used at dilutions around 1:5000 to 1:10,000 for 1 hour at room temperature . When troubleshooting, inclusion of positive controls (tissues known to express GPR18 such as spleen or specific immune cell lines) and negative controls (pre-absorption of the antibody with its immunizing peptide) can help distinguish specific from non-specific signals and validate experimental conditions .

What are the recommended protocols for immunohistochemistry with GPR18 antibodies?

Immunohistochemical detection of GPR18 requires careful attention to tissue preparation, antibody dilution, and detection methods to achieve specific staining with minimal background . For optimal results with brain and other tissues, perfusion fixation with 4% paraformaldehyde followed by cryoprotection and sectioning of frozen tissue at 20-40 μm thickness has been successfully employed in published studies . Antigen retrieval methods may be necessary to unmask epitopes, particularly for fixed-embedded tissues, with citrate buffer (pH 6.0) heating being a common approach, though specific requirements depend on the particular antibody and fixation protocol . Before primary antibody application, effective blocking of non-specific binding sites typically involves incubation with 5-10% normal serum (from the same species as the secondary antibody) in PBS containing 0.1-0.3% Triton X-100 for membrane permeabilization, unless staining is intended to detect only cell surface GPR18 . Primary GPR18 antibodies have been successfully used at dilutions ranging from 1:50 to 1:200 for immunohistochemistry, with overnight incubation at 4°C generally providing optimal results . For visualization, both chromogenic (DAB) and fluorescent detection systems are compatible with GPR18 antibodies, with the latter often preferred for colocalization studies with other markers . When using fluorescent detection, counterstaining with DAPI to visualize cell nuclei provides valuable context for interpreting GPR18 localization patterns, as demonstrated in studies of rat brain sections . Critical controls should include omission of primary antibody, pre-absorption with the immunizing peptide (which should eliminate specific staining), and comparison with tissues known to be positive or negative for GPR18 expression based on other detection methods . These methodological considerations ensure reliable detection and localization of GPR18 in tissues, enabling accurate characterization of its anatomical distribution and potentially its functional implications in different physiological contexts.

What are common problems when using GPR18 antibodies and how can they be resolved?

Researchers working with GPR18 antibodies frequently encounter several technical challenges that can significantly impact experimental outcomes if not properly addressed . High background staining represents a common issue, particularly in immunohistochemistry and immunofluorescence applications, often resulting from insufficient blocking, excessive antibody concentration, or inadequate washing steps; this can typically be resolved by extending blocking times (up to 2 hours), testing more stringent blocking reagents (such as fish gelatin instead of BSA), optimizing antibody dilutions through careful titration experiments, and increasing the number and duration of washing steps . Weak or absent specific signals present another frequent challenge, potentially stemming from low target protein expression, epitope masking during fixation, or degradation during sample preparation; researchers can address these issues by using positive control samples with known GPR18 expression (such as spleen tissue or BV-2 cells), testing alternative fixation protocols or incorporating antigen retrieval steps, and ensuring complete protease inhibition during sample preparation . Multiple bands in Western blot applications often confound interpretation and may result from protein degradation, non-specific binding, or detection of different GPR18 isoforms or post-translationally modified forms; distinguishing true from false signals can be achieved by pre-absorbing the antibody with its immunizing peptide (which should eliminate specific bands), comparing band patterns across multiple antibodies targeting different GPR18 epitopes, and correlating observed molecular weights with theoretical predictions accounting for potential glycosylation or other modifications . Species cross-reactivity limitations can restrict experimental design, necessitating careful antibody selection based on sequence homology between the immunizing peptide and the target species' GPR18 sequence; researchers should consult validation data specifically for their species of interest and consider epitope conservation when selecting antibodies for cross-species studies . Addressing these common challenges through systematic optimization and appropriate controls ensures more reliable and interpretable results when working with GPR18 antibodies across various experimental applications.

What factors affect the reproducibility of GPR18 antibody experiments?

The reproducibility of experiments utilizing GPR18 antibodies depends on multiple methodological factors that must be carefully controlled and documented to ensure consistent results across different laboratories and studies . Antibody selection represents a primary determinant of reproducibility, with particular attention needed for lot-to-lot variations even within the same catalog number; researchers should record detailed antibody information including manufacturer, catalog number, lot number, and, when available, validation data specific to that lot . Sample preparation consistency significantly impacts reproducibility, requiring standardized protocols for tissue fixation, cell lysis, protein extraction, and storage conditions; even minor variations in fixative concentration, incubation times, or temperature fluctuations during storage can alter epitope accessibility and protein integrity . Protocol parameters must be precisely defined and followed, including blocking conditions, antibody dilutions, incubation times and temperatures, washing procedures, and detection methods; these details should be comprehensively documented to facilitate replication by other researchers . The physiological state of the biological system under investigation introduces another variable affecting reproducibility, as GPR18 expression and localization may change with factors such as inflammatory status, cellular activation state, or developmental stage; therefore, careful documentation of animal age, strain, treatment conditions, cell culture conditions, and passage number for cell lines is essential . Technical controls should be consistently incorporated, including positive and negative tissue controls, isotype controls, and blocking peptide controls in each experimental series to provide internal validation of assay performance . Quantification methods introduce additional variables affecting reproducibility, necessitating standardized approaches to image acquisition (microscope settings, exposure times), analysis (thresholding algorithms, region selection), and data normalization (reference proteins, loading controls) . By systematically addressing these factors through detailed methodological documentation, implementation of standardized protocols, inclusion of appropriate controls, and transparent reporting of all experimental parameters, researchers can significantly enhance the reproducibility of GPR18 antibody experiments, facilitating more reliable cross-study comparisons and advancement of knowledge regarding this important receptor.

How can GPR18 antibodies be used to investigate receptor trafficking and internalization?

Advanced imaging techniques combined with strategic antibody applications enable detailed investigation of GPR18 trafficking and internalization dynamics, providing insights into receptor regulation and function . Live cell imaging approaches using antibodies targeting extracellular domains of GPR18 allow researchers to track the receptor's movement on the cell surface before internalization, with fluorescently-labeled antibodies binding to the native receptor without permeabilization; subsequent temperature shifts to 37°C initiate internalization processes that can be monitored in real-time using confocal microscopy . Pulse-chase experimental designs provide temporal resolution of trafficking events, wherein surface GPR18 is first labeled with a primary antibody at 4°C (when internalization is inhibited), followed by washing and reincubation at 37°C for various time intervals before fixation and visualization of receptor redistribution using differently-colored secondary antibodies to distinguish surface-remaining from internalized receptor populations . Co-localization studies with established markers of endocytic compartments (such as early endosome antigen 1, Rab proteins, or lysosomal markers) can reveal the specific intracellular trafficking pathways followed by GPR18 after internalization, requiring dual immunostaining with GPR18 antibodies and organelle markers followed by confocal microscopy and quantitative co-localization analysis . For investigating ligand-induced internalization, researchers can compare trafficking patterns before and after treatment with GPR18 agonists such as N-arachidonoyl glycine (NAGly) or other cannabinoid compounds, requiring careful time-course experiments with antibody detection at various intervals following stimulation . Flow cytometry provides a complementary quantitative approach for measuring internalization rates, wherein surface GPR18 levels are measured before and after ligand exposure using antibodies against extracellular epitopes, with decreased surface staining indicating receptor internalization . These sophisticated applications of GPR18 antibodies, when combined with appropriate controls and quantitative analysis, enable researchers to elucidate the dynamic regulation of this receptor in response to physiological stimuli, pharmacological agents, or pathological conditions, thereby advancing understanding of its cellular functions and potential as a therapeutic target.

What approaches can be used to study GPR18 phosphorylation and post-translational modifications?

Investigating post-translational modifications (PTMs) of GPR18 requires specialized experimental approaches combining immunological techniques with biochemical and mass spectrometry methods . Phosphorylation-specific antibodies, though not yet widely available for GPR18, represent a potential approach for directly detecting phosphorylated forms of the receptor; development of such antibodies would require identification of specific phosphorylation sites through phosphoproteomic analyses and subsequent generation of antibodies specifically recognizing phosphopeptide sequences within GPR18 . In the absence of phospho-specific antibodies, researchers can employ immunoprecipitation (IP) using validated GPR18 antibodies to isolate the receptor from cell lysates, followed by Western blotting with general phospho-detection antibodies (such as anti-phosphoserine, anti-phosphothreonine, or anti-phosphotyrosine) to determine if the receptor undergoes phosphorylation under basal or stimulated conditions . For comprehensive identification of GPR18 PTMs, mass spectrometry-based approaches offer the greatest depth of information; this typically involves immunoprecipitation of GPR18 from cellular systems using validated antibodies, followed by proteolytic digestion and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis to identify modified residues and quantify changes in modification levels under different experimental conditions . Two-dimensional gel electrophoresis combined with Western blotting provides another approach for visualizing different post-translationally modified forms of GPR18, wherein horizontal shifts in protein spots can indicate changes in charge resulting from phosphorylation or other modifications, requiring subsequent spot excision and mass spectrometry for definitive identification . For investigating dynamic regulation of GPR18 PTMs, time-course experiments comparing modification patterns before and after treatment with receptor agonists (such as NAGly), antagonists, or modulators of specific kinases and phosphatases can reveal regulatory mechanisms controlling receptor function . These advanced approaches to studying GPR18 post-translational modifications provide critical insights into the molecular mechanisms regulating receptor activity, trafficking, and signaling, potentially revealing new therapeutic opportunities for modulating GPR18 function in various physiological and pathological contexts.

How can researchers investigate GPR18 interactions with other proteins using antibody-based methods?

Elucidating the interactome of GPR18 provides critical insights into its signaling mechanisms and biological functions, with several antibody-based approaches enabling detailed investigation of protein-protein interactions . Co-immunoprecipitation (co-IP) represents a fundamental technique, wherein validated GPR18 antibodies are used to isolate the receptor and its associated protein complexes from cell or tissue lysates under non-denaturing conditions, followed by Western blotting to detect specific interacting partners such as G-proteins, arrestins, or other signaling molecules; this approach has particular utility for confirming interactions with proteins suspected to participate in GPR18 signaling pathways . Proximity ligation assay (PLA) offers an advanced in situ approach for visualizing protein interactions in their native cellular context, requiring pairs of primary antibodies (one targeting GPR18 and another targeting the putative interacting protein) from different host species, followed by species-specific secondary antibodies conjugated to oligonucleotides that, when in close proximity (<40 nm), can be ligated and amplified to produce fluorescent spots representing interaction sites; this technique provides spatial information about GPR18 interaction networks within cells . For broader interactome mapping, antibody-based pull-down followed by mass spectrometry (IP-MS) enables unbiased identification of GPR18-interacting proteins, wherein the receptor and its complexes are immunoprecipitated using validated antibodies, followed by proteolytic digestion and liquid chromatography-tandem mass spectrometry to identify all associated proteins, with subsequent validation of key interactions using targeted approaches . Bioluminescence resonance energy transfer (BRET) or fluorescence resonance energy transfer (FRET) combined with antibody detection provides complementary approaches for monitoring dynamic interactions in living cells, requiring expression of GPR18 fused to a donor fluorophore/luciferase and potential interacting partners fused to acceptor fluorophores, with subsequent antibody-based verification of expression levels and subcellular localization . When investigating interactions involving both native and recombinant systems, reciprocal co-IP experiments (pulling down with antibodies against either GPR18 or the interacting partner) provide stronger evidence for genuine interactions, particularly when combined with controls such as isotype-matched non-specific antibodies and competitive peptide blocking . These methodological approaches collectively enable researchers to decipher the complex interactome of GPR18, revealing its integration into broader signaling networks and potentially identifying novel targets for therapeutic intervention in GPR18-mediated processes.

What quantitative methods are appropriate for analyzing GPR18 expression levels?

Quantitative analysis of GPR18 expression requires appropriate methodological approaches tailored to the experimental context, with several antibody-based techniques providing complementary information . Western blot densitometry represents a fundamental approach for relative quantification, wherein band intensities for GPR18 are normalized to loading controls (such as β-actin, GAPDH, or Na⁺/K⁺-ATPase for membrane proteins) and compared across experimental conditions; this requires careful validation of linear detection range, consistent exposure times, and appropriate statistical analysis of multiple independent experiments to ensure reliability . Flow cytometry provides powerful single-cell quantification of GPR18 surface expression, with mean fluorescence intensity (MFI) values serving as quantitative metrics; this approach requires careful gating strategies, inclusion of isotype controls for background subtraction, and calibration with fluorescence standards when absolute quantification is needed . For tissue section analysis, quantitative immunohistochemistry/immunofluorescence involves standardized image acquisition followed by digital analysis of staining intensity, optical density, or percentage of positively stained cells within defined regions of interest; this requires consistent staining protocols, standardized microscope settings, and unbiased selection of analysis regions to minimize subjective interpretation . ELISA-based approaches (either standard ELISA or cell-based ELISA for surface expression) offer another quantitative method, requiring development of sandwich antibody pairs with one antibody for capture and another for detection; while not widely reported for GPR18, this approach could provide high-throughput quantification if suitable antibody pairs are validated . For comparison across diverse experimental systems or to establish absolute quantities, quantitative Western blotting against purified GPR18 standards of known concentration can be employed, enabling conversion of relative values to absolute protein amounts . When interpreting quantitative data, researchers should account for potential confounding factors such as antibody affinity variation across different GPR18 conformational states, interference from interacting proteins, and differences in epitope accessibility that might bias detection of certain receptor populations . Through careful selection of quantitative methods appropriate to their experimental questions and rigorous attention to methodological controls and standardization, researchers can generate reliable measurements of GPR18 expression levels that enable meaningful comparisons across experimental conditions, cell types, or disease states.

How can researchers correlate GPR18 antibody staining patterns with functional data?

Establishing meaningful connections between GPR18 localization patterns and functional outcomes requires integrative experimental approaches combining antibody-based detection with targeted functional assays . Spatial-functional correlation in tissue contexts can be achieved through sequential or parallel sectioning approaches, wherein adjacent tissue sections are alternatively processed for GPR18 immunohistochemistry and functional assays such as agonist-stimulated GTPγS binding, calcium imaging, or electrophysiological recordings; this enables approximate mapping of receptor distribution to functional responses within the same anatomical regions . For cellular systems, co-registration techniques combining GPR18 immunofluorescence with live-cell functional imaging provide more direct correlation; this typically involves performing calcium imaging, cAMP measurements, or other real-time functional assays in living cells, followed by fixation and immunostaining for GPR18, with subsequent image overlay to correlate receptor expression patterns with the previously recorded functional responses at the single-cell level . Genetic manipulation approaches offer powerful tools for establishing causal relationships, wherein GPR18 expression is experimentally modified (through overexpression, knockdown, or knockout) followed by parallel assessment of both receptor levels/distribution (using antibody-based methods) and functional outcomes (using appropriate bioassays); this reveals whether changes in GPR18 expression directly impact functional measures such as cell migration, inflammatory responses, or cannabinoid sensitivity . Pharmacological intervention studies provide complementary evidence, with cells or tissues treated with GPR18 ligands (agonists, antagonists, or allosteric modulators) and subsequently analyzed for both changes in receptor localization/expression (using antibody detection) and functional consequences; temporal correlation between receptor trafficking events and functional responses can reveal mechanistic insights into signaling dynamics . Mathematical modeling approaches can integrate antibody-derived quantitative data on receptor expression with dose-response curves from functional assays to establish quantitative relationships between receptor levels and functional outcomes, potentially revealing thresholds, cooperativity, or other non-linear aspects of GPR18 signaling . These integrative approaches, when combined with appropriate controls and statistical analyses, enable researchers to move beyond descriptive observations toward mechanistic understanding of how GPR18 distribution and expression patterns relate to its diverse functional roles in physiological and pathological contexts.